Oncotarget

Research Papers:

Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma

Qi Bai, Li Liu, Wei Xi, Jiajun Wang, Yu Xia, Yang Qu, Ying Xiong, Qilai Long, Jiejie Xu _ and Jianming Guo

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:3112-3120. https://doi.org/10.18632/oncotarget.11258

Metrics: PDF 1999 views  |   HTML 2134 views  |   ?  


Abstract

Qi Bai1,*, Li Liu1,*, Wei Xi1,*, Jiajun Wang1, Yu Xia1, Yang Qu1, Ying Xiong1, Qilai Long1, Jiejie Xu2, Jianming Guo1

1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

*These authors have contributed equally to this work

Correspondence to:

Jiejie Xu, email: [email protected]

Jianming Guo, email: [email protected]

Keywords: clear cell renal cell carcinoma, α-GalNAc α-2, 6-sialyltransferase 1, nomogram, overall survival

Received: March 07, 2016     Accepted: July 18, 2016     Published: August 12, 2016

ABSTRACT

Background: Sialyltransferase ST6GalNAc-1 is highly expressed in tumor cells and associated with tumor aggressiveness and poor prognosis. In the present study, we aimed to investigate the clinical and prognostic significance of sialyltransferase ST6GalNAc-1 in patients with non-metastatic ccRCC.

Results: High expression of ST6GalNAc-1 in tumor tissue was an independent prognostic factor for overall survival (p<0.001) and recurrence free survival (p<0.001) in multivariate analysis. The nomograms could give better prediction for overall survival and recurrence free survival in ccRCC patients.

Methods: 264 patients diagnosed with non-metastatic clear cell renal cell carcinoma were enrolled in the present study. Immunohistochemical staining was performed on tissue microarrays to evaluate the intratumoral ST6GalNAc-1 expression. Kaplan-Meier method and Cox proportional hazard model were applied to assess the prognostic value of ST6GalNAc-1. Nomograms were generated to refine individual risk stratification in ccRCC patients.

Conclusion: ST6GalNAc-1 was an independent adverse prognostic factor for both overall survival and recurrence free survival in patients with non-metastatic ccRCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11258